A series of novel substituted quinazolinone derivatives was synthesized and characterized by 1 H NMR and LC-MS spectral techniques. The overall results of the antibacterial tests showed that these compounds had better bacteriostatic activity against Grampositive bacteria than their parent compounds. Furthermore, compounds 5f, 6b and 6f showed potent activity against Enterococcus faecalis (ATCC 51299), with MIC values <0.2 g/mL. Compounds 4e, 5g, 5e and 6c showed excellent activity, with MIC values <0.4 g/mL. Gram-negative bacteria Escherichia coli (ATCC 35218) and Klebsiella (ATCC 700603) are more resistant to lower concentrations of the synthesized compounds. The anti-inflammatory activities of the synthesized compounds were evaluated using the Carrageenan-induced rat Paw oedema method and ibuprofen as a standard drug. Compounds 4a and 4b exhibited good activity. Additionally, docking stimulations were performed to position compounds 4e, 4g, 5e, 5f, 6a and 6f into the EGFR kinase domain and human oestrogen receptor active site to determine probable binding information. This study indicated that compounds 6a and 6f have significant binding activities of 58.36 and 57.67 kJ mol −1 , respectively.
Introduction
There are many quinazolinone derivatives that are considered to be important chemical synthons with various physiological significances and pharmaceutical utilities (Fig. 1) . They possess a variety of biological effects, including antihypertensive [1, 2] , antimicrobial [3, 4] , antihyperlipidemic [5] , anti-inflammatory [6] [7] [8] [9] and anticonvulsant [10, 11] activities. Moreover, many quinazolines have contributed to the search for an ultimate antitumor chemotherapeutic agent [12] [13] [14] . A literature survey revealed that the presence of a substi- tuted aromatic ring at position 3 and a methyl group at position 2 are necessary requirements for central nervous system depression and anticonvulsant activities. Modification of the methyl group by some other chemical moieties yielded structural analogues with anticonvulsant activities. Recently, we have been involved in a program that aims to synthesize new heterocyclic compounds from a cyanoacetanilide precursor that possess biologically active properties and can be used as potential antimicrobial agents [15, 16] . In this context and because of the increased interest in quinazoline derivatives, some new quinazoline derivatives have been synthesized and used to study biological activity.
Quinazolinones that have fused pyrimidine nuclei ( Fig. 2) play very important roles because of their pharmacological properties, which include wide applications in medicinal chemistry [17] [18] [19] . Currently, much attention has been paid to pyrimidine and condensed pyrimidine compounds for their worthwhile and interesting biological properties [20] . The pyrimidine nucleus is embedded in a large number of alkaloids, drugs, antibiotics and agrochemical agents [21] . Pyrimidine derivatives play a vital role in many biological processes and have potential anticancer and analgesic activities [22, 23] . Some pyrimidines and their derivatives are found to possess anti-HIV activity [24] .
The present paper aims to provide insights on the current medicinal aspects of quinazolinone heterocycles ( Fig. 1 ) as well as to give a brief discussion of their chemistry.
Materials and methods
All of the reagents were purchased from Aldrich. Final purifications were carried out using an Isolera One (Biotage). TLC experiments were performed on alumina-backed silica gel GF254. The plates were illuminated under UV light (254 nm). Melting points were determined using a Buchi B-545 and were uncorrected. 1 H and 13 C NMR spectra were recorded on Bruker (400 MHz) spectrometer instruments. The chemical shifts are reported in ppm (δ) with reference to the internal standard TMS. The signals are designated as follows: s, singlet; d, doublet; dd, doublet of doublet; t, triplet; m, multiplet; brs, broad singlet; and brt, broad triplet. The molecular weights of the unknown compounds were characterized using a LC-MS Agilent 1200 series.
2-{[4-(Trifluoromethoxy) benzyl] amino} benzamide 1
4-Trifluoromethoxy benzaldehyde (20.1 g, 105.8 mmol) and sodiumcyanoborohydride (9.8 g, 176.4 mmol) were added to a solution of 2-aminobenzamide (12 g, 88.2 mmol) in DMF/THF (120 mL, 1:1). The reaction mixture was stirred at room temperature for 18 h. The reaction was monitored by TLC and extracted with ethyl acetate. The organic layer was separated and dried over Na 2 SO 4 followed by evaporation to obtain the crude product, which was then purified by column chromatography (silica gel). 
Preparation of 1 -[4-(trifluoromethoxy) benzyl]-1 H-spiro [piperidine-4, 2 -quinazolin]-4 (3 H)-one(3)
HCl in dioxane (100 mL) was added to a solution of methyl 4-{[(2-carbamoylphenyl)amino] methyl}benzoate 2 (17 g, 34.6 mmol) in 1,4-dioxane (50 mL). The reaction mixture was stirred at room temperature for 6 h. The reaction was monitored by TLC. The resulting solution was concentrated and basified with sodium bicarbonate solution, and the organic layer was separated and dried over sodium sulphate. The filtrate from evaporation gave the pure product.
Compound 3 was obtained as an off-white solid; 58% yield. 1 
General procedure for the synthesis of the title compounds (4a-g)
Pyridine (3 mmol) and sulphonyl chloride (1.5 mmol) were added to a cooled solution of 3 (1 mmol) in 1,2-dichloroethane (10 mL). The reaction mixture was stirred at room temperature for 8 h. The progress of the reaction was monitored by TLC. The resulting solution was concentrated and extracted with ethyl acetate. The organic layer was dried over Na 2 SO 4 , and evaporation of the solvent gave the product. The crude product was purified with an Isolera One using a different solvent system [17]. 
1-(Methylsulphonyl)-1 -(4-(trifluoromethoxy) benzyl)-1 H-spiro [piperidine-4,2 -quinazolin]-4 (3 H)-one (4a)

1-((4-Propylphenyl) sulphonyl)-1 -(4-(trifluoromethoxy) benzyl)-1 H-spiro [piperidine-4,2 -quinazolin]-4 (3 H)-one (4e)
Compound 4e was obtained as an off-white solid. mp 239.6-243.1 • C; 67% yield. 1 
1-((2-Chlorophenyl) sulphonyl)-1 -(4-(trifluoromethoxy) benzyl)-1 H-spiro [piperidine-4,2 -quinazolin]-4 (3 H)-one (4f)
Compound 4f was obtained as a pale yellow solid. mp 187.0-189.9 • C; 53% yield. 1 
1-((5-Bromothiophen-2-yl) sulphonyl)-1 -(4-(trifluoromethoxy) benzyl)-1 H-spiro [piperidine-4,2 -quinazolin]-4 (3 H)-one (4g)
Compound 4g 
General procedure for the synthesis of the title compounds (5a-f)
Acetic acid (5 mmol), aldehydes (1.5 mmol) and sodium triacetoxyborohydride (1.5 mmol) were added to a solution of 3 (1 mmol) in methanol (10 mL). The reaction mixture was stirred at room temperature for 6 h. The reaction was monitored by TLC. The resultant solution mixture was concentrated and extracted with ethyl acetate and dried over Na 2 SO 4 . Evaporation of the solvent gave the crude product, which was then purified by Biotage [17].
1-Phenethyl-1 -(4-(trifluoromethoxy) benzyl)-1 H-spiro [piperidine-4, 2 -quinazolin]-4 (3 H)-one (5a)
Compound 5a was obtained as a white solid. mp 201.1-203.6 • C; 45% yield. 1 
3-((4 -Oxo-1 -(4-(trifluoromethoxy)benzyl)-3 , 4 -dihydro-1 H spiro[piperidine-4,2 -quinazolin]-1-yl)methyl)benzonitrile (5b)
Compound 5b was obtained as a white solid. mp 187.3-189.9 • C; 59% yield. 1 
1-(3-Chlorobenzyl)-1 -(4-(trifluoromethoxy) benzyl)-1 H-spiro[piperidine-4,2 -quinazolin]-4 (3 H)-one (5c)
1-(Pyridin-4-ylmethyl)-1 -(4-(trifluoromethoxy)benzyl)-1 H-spiro[piperidine-4,2 -quinazolin]-4 (3 H)-one (5d)
Compound 5d was obtained as a white solid. mp 132.1-134.8 • C; 32% yield. 1 
1-(3-Ethoxybenzyl)-1 -(4-(trifluoromethoxy) benzyl)-1 H-spiro[piperidine-4,2 -quinazolin]-4 (3 H)-one (5e)
Compound 5e was obtained as a white solid. mp 122.7-125.2 • C; 46% yield. 1 
1-(4,4,4-Trifluorobutyl)-1 -(4-(trifluoromethoxy)benzyl)-1 H-spiro[piperidine-4,2 -quinazolin]-4 (3 H)-one (5f)
Compound 5f was obtained as a white solid. mp 179.1-182.6 • C; 62% yield. 1 
General procedure for the synthesis of the title compounds (6a-f)
A solution of diisopropyl ethylamine (3 mmol), substituted acids (1.2 mmol), 1-hydrobenzotriazole (1.5 mmol) and EDC.HCl (3 mmol) was added to a solution of 3 (1 mmol) in N,N -dimethylformamide (5 mL). The reaction mixture was stirred at room temperature for 10 h. The progress of the reaction was monitored by TLC. The obtained solution was concentrated and extracted with ethyl acetate and dried over Na 2 SO 4 . The crude product was purified by Biotage [17]. 
1-(3-Fluorobenzoyl)-1 -(4-(trifluoromethoxy)benzyl)-1 H spiro [piperidine-4,2 -quinazolin]-4 (3 H)-one (6a)
Compound 6a was obtained as a white solid. mp 232.5-235.2
1-(Furan-3-carbonyl)-1 -(4-(trifluoromethoxy)benzyl)-1 H spiro [piperidine-4,2 -quinazolin]-4 (3 H)-one (6c)
Compound 6c was obtained as a white solid. 
1-(1H-1,2,3-triazole-4-carbonyl)-1 -(4-(trifluoromethoxy)benzyl)-1 H-spiro[piperidine-4,2 -quinazolin]-4 (3 H)-one (6d)
Compound 6d was obtained as a white solid. mp 232.0-236.8 • C; 61% yield. 1 H NMR 400 MHz, DMSO- 
1-(Cyclopropanecarbonyl)-1 -(4-(trifluoromethoxy)benzyl)-1 H-spiro[piperidine-4,2 -quinazolin]-4 (3 H)-one (6e)
Compound 6e was obtained as a white solid. mp 219.1-220.2 • C; 77% yield. 1 
5-[(1 -{4-Trifluromethoxybenzyl}-4 -oxo-3 ,4 -dihydro-1H,1 H-spiro[piperidine-4,2 -quinazolin]-1-yl)carbonyl]pyrimidine-2,4(1H,3H)-dione (6f)
Compound 6f was obtained as a white solid. mp 211.7-215.5 • C; 36% yield. 1 
Results and discussion
The synthesis of the final compounds, 4a-g, 5a-f and 6a-f, is outlined in Scheme 1. We adopted the reported procedure with slight modifications to prepare target scaffold 3. The synthesis of 2-{ [4-(trifluoromethoxy) benzyl]amino}benzamide 1 was completed by reacting 4-(trifluoromethoxy)benzaldehyde in the presence of catalytic amounts of acetic acid in dry DMF/THF (1:1) and sodium cyanoborohydride. Intermediate 2 was obtained by condensation followed by cyclodehydration using 1-propane phosphonic acid cyclic anhydride. Its structure was further confirmed by its mass spectrometry, which showed a mass peak of 492.2 (m+1), matching the molecular formula C 25 H 28 Table 2 Gram-negative study with the synthesized compounds. 
MIC Results
E.coli
which gave a good yield. The titled compounds 4a-g were obtained by reacting scaffold 3 with different substituted aryl and alkyl sulphonyl chlorides at 0 • C in 1,2-dichloroethane using triethylamine as a base. Compounds 5a-f were synthesized by reacting scaffold 3 with substituted aryl and alkyl aldehydes, while compounds 6a-f were obtained by reacting the scaffold with different acids in the presence of base, 1-hydrobenzotriazole and EDC·HCl at room temperature, as shown in Scheme 1. The obtained crude product was purified on a Biotage parallel column purifier or by glass column chromatography using chloroform, methanol, petroleum ether and ethyl acetate as the eluent. The newly synthesized compounds were characterized by IR spectroscopy, 1 H and 13 C NMR and LC-MS spectral techniques.
Pharmacology
Anti-inflammatory screening
Adult Wistar rats of either sex weighing between 120-150 g were used for this study. The animals were given a pelleted diet ad libitum and kept under a 12 h/12 h light/dark cycle. All of the experimental procedures were carried out according to the guidelines of the Committee for the Purpose of Control and Supervisions on Experimentation on Animals (CPCSEA) and were approved by the Institutional Animal Ethics Com- Table 3 Gram-positive study with the synthesized compounds. 
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Evaluation of anti-inflammatory activity
Evaluation of the anti-inflammatory activity of the synthesized compounds was performed using the carrageenan-induced rat paw oedema model using Diclofenac sodium as the reference drug as described in the literature [25] . Mean changes in paw oedema thickness in animals pre-treated with the tested compounds after 0, 60 and 180 min were measured from the induction of inflammation. We also measured the percent oedema inhibition by the tested compounds (Table 1) The animals were divided into twelve groups containing six animals each. One group served as the standard, another group served as the control and the remaining groups were used to test the synthesized compounds. The rats were dosed orally with the test drugs (100 mg/kg p.o) and the standard drug Diclofenac (100 mg/kg p.o) after suspending them in sodium carboxymethyl cellulose, which is a vehicle that as given alone to the control group. Food was withdrawn overnight with adequate water before the experiment. Thirty minutes after administering the test compounds, Carrageenan solution (1% w/v) was injected into the sub-plantar region of the left hind paw of the control, standard and test groups. The paw volumes from all of the groups were measured with a plethysmograph by the water displacement method at 0, 60 and 180 min intervals. The percent inhibition was calculated with the following equation:
where Vc is the control oedema of control and Vt is the test oedema.
Figs. 7-8. (7) 5e, COX-2 enzyme. (8) . 5e, COX-1 enzyme.
Figs. 9-10. (9) 5f, COX-2 enzyme. (10) 5f COX-1 enzyme.
Statistical analysis
The values are expressed as the mean ± SEM (Standard Error Mean), and the data were analysed by one way ANOVA. p < 0.05 was considered significant.
The test compounds 4a, 4b, 4g, and 5a showed significant anti-inflammatory activity at 3 h against the carrageenan injection, suggesting that these compounds might inhibit the release of prostaglandin-like substances from phlogenic stimuli. The paw volume was significantly reduced (p < 0.05) in all of the groups treated with the test compounds compared to the control group. Among the compounds, 4a showed the maximum inflammatory effect. However, the anti-inflammatory activities produced by compounds 4a, 4b, 4g, and 5a were found to be less effective than the reference stan- dard diclofenac sodium. The % inhibition of oedema at 3 h after carrageenan challenge produced by these compounds and the standard diclofenac sodium was 66.66%, whereas 4a exhibited a 56.19% inhibition.
Antibacterial studies
Antibacterial activity was examined with the cupplate method by measuring the inhibition zone. All of the test compounds were screened for antibacterial activity against Gram-positive bacteria Staphylococcus aureus and E. faecalis and Gram-negative bacteria E. coli; Klebsiella were used as the antibacterial reference at a concentration of 100-0.2 g/mL [26] .
As shown in Tables 2 and 3 , the synthesized compounds exhibited a broad spectrum of activity, with MIC values ranging from 100-0.2 g/mL against both Gram-positive and Gram-negative bacteria. Among the Gram-positive bacteria tested, E. faecalis (ATCC 51299) showed a relatively high sensitivity towards the title compounds. Compounds 5e and 6a gave the best inhibitory activity against S. aureus (ATCC 25923), with MIC values <0.4 g/mL, while compounds 4e and 6d also showed good activity against S. aureus (ATCC 25923), with MIC values <0.8 g/mL. Furthermore compounds 5f, 6b and 6f showed potent activity against E. faecalis (ATCC 51299), with MIC values <0.2 g/mL. Compounds 4e, 5g, 5e, and 6c showed excellent activity, with MIC values <0.4 g/mL. Gram-negative bacteria E. coli (ATCC 35218) and Klebsiella (ATCC 700603) showed more resistance to lower concentrations.
A spiroquinazolinone derivative at positions 2 and 3 shows good biological activity. These novel quinazolinones are used for the treatment of potential antihypertensive agents and are useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase and gastroesophageal reflux disease. Along with this compound, compounds 4e, 4g, 5e, 5f, 6a, 6b, 6c, and 6f also showed good antimicrobial activity at the MIC level because their functional groups are attached to the parent skeleton.
Molecular docking using HEX 8.0
Docking calculations were performed to determine the potential anti-inflammatory activities of lead compounds 4e, 4g, 5e, 5f, 6a and 6f by docking them with the HEX 8.0 software into the 3D catalytic sites in the COX-2 (pdb code: 1cx2) and COX-1 (pdb code: 1eqg) enzymes (Table 4) . Docking picture of the synthesized compound with the COX-2 (pdb code: 1cx2) and COX-1 (pdb code: 1eqg) enzymes (Figs. 3-4, Figs. 5-6, Figs. 7-8,  Figs. 9-10, Figs. 11-12 and Figs. 13-14) .
We correlated the dock inhibitor study with the catalytic sites in the COX isoenzymes and obtained binding free energies with inhibitory activities for the compounds. Briefly, the results of the docking experiments for the synthesized compounds 4e, 4g, 5e, 5f, 6a and 6f, which displayed more potential at the MIC level, were compared with the known non-selective COX inhibitor ibuprofen. The results were evaluated in terms of binding energy [27, 28] . Table 5 shows the binding energies of the top-scored molecules during docking experiments of the synthesised compounds.
All of the synthesized compounds displayed improved binding energies compared to active ibuprofen. Although some of synthesized compounds are chiral, the differences in the binding energies of the enantiomers were not significant. The terminal trifluoromethyl group attached to compounds 6a and 6f showed very good docking scores of 58.36 and −57.67 kJ mol −1 , respectively. Compounds 6a, which has one fluorine atom, compared better with 6f, which displayed the high- est docking score against the COX-2 isoenzyme 1cx2 receptor. Similarly, the docking scores for all of the compounds were recorded using the COX-1 isoenzyme 1eqg receptor, and they all showed binding energies between −0.01 and −0.03.
Conclusions
In summary, novel sulphonamide (4a-g), tert-amine (5a-f) and amide (6a-f) derivatives were synthesized at an excellent yield and characterized by IR, 1 H, 13 C NMR and LC-MS studies. The synthesized compounds were screened for antibacterial activities against various Gram-positive and Gram-negative bacteria. Among the synthesized compounds, 5e and 6a displayed the best inhibitory activities against S. aureus (ATCC 25923), with MIC values <0.4 g/mL. Compounds 4e and 6d also showed good activity against S. aureus (ATCC 25923), with MIC values <0.8 g/mL. Furthermore, compounds 5f, 6b and 6f showed potent activity against E. faecalis (ATCC 51299), with MIC values <0.2 g/mL. Compounds 4e, 5g, 5e and 6c showed excellent activity, with MIC values <0.4 g/mL. Gram-negative bacteria E. coli (ATCC 35218) and Klebsiella (ATCC 700603) showed more resistance to lower concentrations of the derivatives. Finally, it appears that the promising activity of quinazolinones may prove advantageous for pharmacological applications.
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